Evidence map›Paper›PMID 23505372›Full record

ArticlePLoS pathogens2013

Fates of retroviral core components during unrestricted and TRIM5-restricted infection.

Sebla B Kutluay, David Perez-Caballero, Paul D Bieniasz

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. The cyclophilin A-binding loop of the capsid regulates the human TRIM5α sensitivity of nonpandemic HIV-1.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Review
  7. Review
  8. Review
  9. The Roles of TRIMs in Antiviral Innate Immune Signaling.Frontiers in cellular and infection microbiology · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Restriction of HIV-1 and other retroviruses by TRIM5.Nature reviews. Microbiology · 2019
    Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sebla B KutluayAaron Diamond AIDS Research Center, Laboratory of Retrovirology, The Rockefeller University, New York, New York, United States of America.
David Perez-Caballero
Paul D Bieniasz
Rockefeller University · US

Funding

Discovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9M
Howard Hughes Medical InstituteNIAID NIH HHS R37 AI064003NIAID NIH HHS R37AI064003
6 · The paper itself

Abstract

TRIM5 proteins can restrict retroviral infection soon after delivery of the viral core into the cytoplasm. However, the molecular mechanisms by which TRIM5α inhibits infection have been elusive, in part due to the difficulty of developing and executing biochemical assays that examine this stage of the retroviral life cycle. Prevailing models suggest that TRIM5α causes premature disassembly of retroviral capsids and/or degradation of capsids by proteasomes, but whether one of these events leads to the other is unclear. Furthermore, how TRIM5α affects the essential components of the viral core, other than capsid, is unknown. To address these questions, we devised a biochemical assay in which the fate of multiple components of retroviral cores during infection can be determined. We utilized cells that can be efficiently infected by VSV-G-pseudotyped retroviruses, and fractionated the cytosolic proteins on linear gradients following synchronized infection. The fates of capsid and integrase proteins, as well as viral genomic RNA and reverse transcription products were then monitored. We found that components of MLV and HIV-1 cores formed a large complex under non-restrictive conditions. In contrast, when MLV infection was restricted by human TRIM5α, the integrase protein and reverse transcription products were lost from infected cells, while capsid and viral RNA were both solubilized. Similarly, when HIV-1 infection was restricted by rhesus TRIM5α or owl monkey TRIMCyp, the integrase protein and reverse transcription products were lost. However, viral RNA was also lost, and high levels of preexisting soluble CA prevented the determination of whether CA was solubilized. Notably, proteasome inhibition blocked all of the aforementioned biochemical consequences of TRIM5α-mediated restriction but had no effect on its antiviral potency. Together, our results show how TRIM5α affects various retroviral core components and indicate that proteasomes are required for TRIM5α-induced core disruption but not for TRIM5α-induced restriction.

Indexed as

AnimalsAntiviral Restriction FactorsCapsidCarrier ProteinsCHO CellsCricetinaeHEK293 CellsHIV-1HumansProteasome Endopeptidase ComplexProteasome InhibitorsReverse Transcriptase InhibitorsRNA-Directed DNA PolymeraseRNA, ViralTripartite Motif ProteinsUbiquitin-Protein LigasesAntiviral Restriction FactorsCarrier ProteinsProteasome Endopeptidase ComplexProteasome InhibitorsReverse Transcriptase InhibitorsRNA-Directed DNA PolymeraseRNA, ViralTRIM5 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesViral Core Proteins

Identifiers

PMID23505372
PMCPMC3591316
OpenAlexW1998581214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.